MIM
TXMD icon

MetLife Investment Management’s TherapeuticsMD TXMD Stock Holding History

MetLife Investment Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,972
Closed -$110K – 2552
2021
Q3 		$110K Buy
2,972
+1,968
+196% +$87.3K ﹤0.01% 2403
2021
Q2 		$59.7K Sell
1,004
-1,841
-65% -$112K ﹤0.01% 2422
2021
Q1 		$191K Buy
2,845
+2,438
+599% +$191K ﹤0.01% 2079
2020
Q4 		$24.6K Sell
407
-434
-52% -$29.6K ﹤0.01% 2262
2020
Q3 		$66.5K Sell
841
-1,260
-60% -$100K ﹤0.01% 2259
2020
Q2 		$131K Buy
2,101
+1,161
+124% +$67.6K ﹤0.01% 2128
2020
Q1 		$49.8K Sell
940
-1,149
-55% -$114K ﹤0.01% 2226
2019
Q4 		$253K Buy
2,089
+490
+31% +$70.5K ﹤0.01% 1847
2019
Q3 		$290K Sell
1,599
-743
-32% -$105K ﹤0.01% 1728
2019
Q2 		$305K Buy
2,342
+762
+48% +$137K ﹤0.01% 1777
2019
Q1 		$385K Hold
1,580
– – ﹤0.01% 1612
2018
Q4 		$301K Hold
1,580
– – ﹤0.01% 1678
2018
Q3 		$518K Hold
1,580
– – 0.01% 1519
2018
Q2 		$493K Buy
1,580
+180
+13% +$55K 0.01% 1410
2018
Q1 		$341K Hold
1,400
– – ﹤0.01% 1611
2017
Q4 		$423K Buy
+1,400
New +$390K ﹤0.01% 1494

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's TXMD Position: Q4 2021 in Review

MetLife Investment Management sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 2,972 shares — an estimated $110K sold.

MetLife Investment Management first reported a position in TXMD in Q4 2017 and held it in 16 quarters. The position peaked at $518K in Q3 2018. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

  • MetLife Investment Management reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 2,972 TherapeuticsMD shares in Q4 2021, an estimated $110K.
  • MetLife Investment Management first reported a position in TherapeuticsMD in Q4 2017 and held it in 16 quarters.
  • MetLife Investment Management's TherapeuticsMD position peaked at $518K in Q3 2018.
  • 131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.